

Amar Gajjar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9171/publications.pdf>

Version: 2024-02-01

245
papers

31,409
citations

8181

76
h-index

4645

170
g-index

251
all docs

251
docs citations

251
times ranked

21432
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	27.8	1,872
2	Molecular subgroups of medulloblastoma: the current consensus. <i>Acta Neuropathologica</i> , 2012, 123, 465-472.	7.7	1,536
3	Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. <i>Nature Genetics</i> , 2012, 44, 251-253.	21.4	1,402
4	The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. <i>Nature Genetics</i> , 2014, 46, 444-450.	21.4	871
5	Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4202-4208.	1.6	834
6	Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. <i>Lancet Oncology</i> , The, 2006, 7, 813-820.	10.7	811
7	The whole-genome landscape of medulloblastoma subtypes. <i>Nature</i> , 2017, 547, 311-317.	27.8	787
8	Radial glia cells are candidate stem cells of ependymoma. <i>Cancer Cell</i> , 2005, 8, 323-335.	16.8	758
9	Late neurocognitive sequelae in survivors of brain tumours in childhood. <i>Lancet Oncology</i> , The, 2004, 5, 399-408.	10.7	744
10	Novel mutations target distinct subgroups of medulloblastoma. <i>Nature</i> , 2012, 488, 43-48.	27.8	742
11	Subtypes of medulloblastoma have distinct developmental origins. <i>Nature</i> , 2010, 468, 1095-1099.	27.8	710
12	Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. <i>Nature Genetics</i> , 2013, 45, 602-612.	21.4	704
13	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	28.9	702
14	Genomics Identifies Medulloblastoma Subgroups That Are Enriched for Specific Genetic Alterations. <i>Journal of Clinical Oncology</i> , 2006, 24, 1924-1931.	1.6	617
15	Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2011, 29, 1424-1430.	1.6	609
16	C11orf95â€“RELA fusions drive oncogenic NF-Î²B signalling in ependymoma. <i>Nature</i> , 2014, 506, 451-455.	27.8	559
17	Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease. <i>Journal of Clinical Oncology</i> , 2010, 28, 3061-3068.	1.6	558
18	Challenges to curing primary brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 509-520.	27.6	540

#	ARTICLE	IF	CITATIONS
19	Enhancer hijacking activates GF11 family oncogenes in medulloblastoma. <i>Nature</i> , 2014, 511, 428-434.	27.8	520
20	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. <i>Acta Neuropathologica</i> , 2016, 131, 821-831.	7.7	478
21	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. <i>Cancer Cell</i> , 2016, 29, 379-393.	16.8	438
22	Atypical Teratoid/Rhabdoid Tumors (ATRT): Improved Survival in Children 3 Years of Age and Older With Radiation Therapy and High-Dose Alkylator-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 1491-1499.	1.6	384
23	Medulloblastoma. <i>Nature Reviews Disease Primers</i> , 2019, 5, 11.	30.5	376
24	Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. <i>Journal of Clinical Oncology</i> , 2015, 33, 2646-2654.	1.6	368
25	Patterns of Intellectual Development Among Survivors of Pediatric Medulloblastoma: A Longitudinal Analysis. <i>Journal of Clinical Oncology</i> , 2001, 19, 2302-2308.	1.6	356
26	Neurocognitive Consequences of Risk-Adapted Therapy for Childhood Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 5511-5519.	1.6	339
27	Cross-species genomics matches driver mutations and cell compartments to model ependymoma. <i>Nature</i> , 2010, 466, 632-636.	27.8	324
28	Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. <i>Acta Neuropathologica</i> , 2016, 131, 833-845.	7.7	288
29	Genome-Wide Analyses Identify Recurrent Amplifications of Receptor Tyrosine Kinases and Cell-Cycle Regulatory Genes in Diffuse Intrinsic Pontine Glioma. <i>Journal of Clinical Oncology</i> , 2011, 29, 3999-4006.	1.6	286
30	Resolving medulloblastoma cellular architecture by single-cell genomics. <i>Nature</i> , 2019, 572, 74-79.	27.8	273
31	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. <i>Acta Neuropathologica</i> , 2017, 133, 5-12.	7.7	271
32	Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. <i>Journal of Pathology</i> , 2009, 218, 172-181.	4.5	270
33	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. <i>Lancet Oncology</i> , The, 2018, 19, 785-798.	10.7	268
34	Cytogenetic Prognostication Within Medulloblastoma Subgroups. <i>Journal of Clinical Oncology</i> , 2014, 32, 886-896.	1.6	263
35	Clinical, Histopathologic, and Molecular Markers of Prognosis: Toward a New Disease Risk Stratification System for Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 984-993.	1.6	261
36	Anterior Hypopituitarism in Adult Survivors of Childhood Cancers Treated With Cranial Radiotherapy: A Report From the St Jude Lifetime Cohort Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 492-500.	1.6	216

#	ARTICLE	IF	CITATIONS
37	Survival and Neurodevelopmental Outcome of Young Children With Medulloblastoma at St Jude Children's Research Hospital. <i>Journal of Clinical Oncology</i> , 1999, 17, 3720-3728.	1.6	212
38	Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. <i>Neuro-Oncology</i> , 2013, 15, 97-103.	1.2	212
39	Neurocognitive deficits in medulloblastoma survivors and white matter loss. <i>Annals of Neurology</i> , 1999, 46, 834-841.	5.3	204
40	Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. <i>Acta Neuropathologica</i> , 2018, 136, 211-226.	7.7	199
41	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. <i>Cancer Cell</i> , 2016, 30, 891-908.	16.8	191
42	Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group. <i>Journal of Neurosurgery: Pediatrics</i> , 2006, 105, 444-451.	1.3	183
43	Processing Speed, Attention, and Working Memory After Treatment for Medulloblastoma: An International, Prospective, and Longitudinal Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3494-3500.	1.6	181
44	Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study. <i>Clinical Cancer Research</i> , 2013, 19, 6305-6312.	7.0	180
45	Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. <i>Acta Neuropathologica</i> , 2019, 138, 309-326.	7.7	180
46	Immediate Neurocognitive Effects of Methylphenidate on Learning-Impaired Survivors of Childhood Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 1802-1808.	1.6	177
47	Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape. <i>Journal of Clinical Oncology</i> , 2015, 33, 2986-2998.	1.6	175
48	Endocrine Outcomes for Children With Embryonal Brain Tumors After Risk-Adapted Craniospinal and Conformal Primary-Site Irradiation and High-Dose Chemotherapy With Stem-Cell Rescue on the SJMB-96 Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 1112-1118.	1.6	174
49	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	1.6	160
50	Multi-Institution Prospective Trial of Reduced-Dose Craniospinal Irradiation (23.4 Gy) Followed by Conformal Posterior Fossa (36 Gy) and Primary Site Irradiation (55.8 Gy) and Dose-Intensive Chemotherapy for Average-Risk Medulloblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 782-787.	0.8	158
51	Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 768-784.	10.7	151
52	Feasibility of Four Consecutive High-Dose Chemotherapy Cycles With Stem-Cell Rescue for Patients With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor After Craniospinal Radiotherapy: Results of a Collaborative Study. <i>Journal of Clinical Oncology</i> , 2001, 19, 2696-2704.	1.6	148
53	Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. <i>Lancet Oncology</i> , The, 2012, 13, 838-848.	10.7	148
54	Understanding the Cognitive Impact on Children Who are Treated for Medulloblastoma. <i>Journal of Pediatric Psychology</i> , 2007, 32, 1040-1049.	2.1	144

#	ARTICLE	IF	CITATIONS
55	White Matter Lesions Detected by Magnetic Resonance Imaging After Radiotherapy and High-Dose Chemotherapy in Children With Medulloblastoma or Primitive Neuroectodermal Tumor. <i>Journal of Clinical Oncology</i> , 2004, 22, 4551-4560.	1.6	129
56	Intellectual and Functional Outcome of Children 3 Years Old or Younger Who Have CNS Malignancies. <i>Journal of Clinical Oncology</i> , 2005, 23, 7152-7160.	1.6	129
57	Sex Differences in Prognosis for Children With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 1999, 17, 818-818.	1.6	128
58	Pemetrexed and Gemcitabine as Combination Therapy for the Treatment of Group3 Medulloblastoma. <i>Cancer Cell</i> , 2014, 25, 516-529.	16.8	128
59	Molecular Insights into Pediatric Brain Tumors Have the Potential to Transform Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 5630-5640.	7.0	124
60	Amifostine Protects Against Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3749-3755.	1.6	119
61	Comparison of CSF Cytology and Spinal Magnetic Resonance Imaging in the Detection of Leptomeningeal Disease in Pediatric Medulloblastoma or Primitive Neuroectodermal Tumor. <i>Journal of Clinical Oncology</i> , 1999, 17, 3234-3237.	1.6	111
62	Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. <i>Nature Genetics</i> , 2015, 47, 263-266.	21.4	109
63	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). <i>Journal of Clinical Oncology</i> , 2021, 39, 822-835.	1.6	106
64	An Integrated InÂVitro and InÂVivo High-Throughput Screen Identifies Treatment Leads for Ependymoma. <i>Cancer Cell</i> , 2011, 20, 384-399.	16.8	105
65	Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Childrenâ€™s Oncology Group Trial ACNS0333. <i>Journal of Clinical Oncology</i> , 2020, 38, 1175-1185.	1.6	102
66	Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. <i>Acta Neuropathologica</i> , 2012, 124, 247-257.	7.7	101
67	Examination of risk factors for intellectual and academic outcomes following treatment for pediatric medulloblastoma. <i>Neuro-Oncology</i> , 2014, 16, 1129-1136.	1.2	99
68	Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. <i>Oncotarget</i> , 2017, 8, 69295-69302.	1.8	99
69	Low-grade astrocytoma with neuraxis dissemination at diagnosis. <i>Journal of Neurosurgery</i> , 1995, 83, 67-71.	1.6	96
70	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. <i>Nature</i> , 2020, 580, 396-401.	27.8	94
71	Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2685-2697.	1.6	91
72	What's new in neuro-oncology? Recent advances in medulloblastoma. <i>European Journal of Paediatric Neurology</i> , 2003, 7, 53-66.	1.6	90

#	ARTICLE	IF	CITATIONS
73	Comparison of Lumbar and Shunt Cerebrospinal Fluid Specimens for Cytologic Detection of Leptomeningeal Disease in Pediatric Patients With Brain Tumors. <i>Journal of Clinical Oncology</i> , 1999, 17, 1825-1825.	1.6	89
74	Chemotherapy for Malignant Brain Tumors of Childhood. <i>Journal of Child Neurology</i> , 2008, 23, 1149-1159.	1.4	85
75	UGT1A1 Promoter Genotype Correlates With SN-38 Pharmacokinetics, but Not Severe Toxicity in Patients Receiving Low-Dose Irinotecan. <i>Journal of Clinical Oncology</i> , 2007, 25, 2594-2600.	1.6	84
76	Silent Lacunar Lesions Detected by Magnetic Resonance Imaging of Children With Brain Tumors: A Late Sequela of Therapy. <i>Journal of Clinical Oncology</i> , 2000, 18, 824-824.	1.6	80
77	Phase II Trial of Response-Based Radiation Therapy for Patients With Localized CNS Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 3283-3290.	1.6	78
78	Results of a Phase II Upfront Window of Pharmacokinetically Guided Topotecan in High-Risk Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor. <i>Journal of Clinical Oncology</i> , 2004, 22, 3357-3365.	1.6	74
79	White matter integrity is associated with cognitive processing in patients treated for a posterior fossa brain tumor. <i>Neuro-Oncology</i> , 2012, 14, 1185-1193.	1.2	74
80	Children's Oncology Group's 2013 blueprint for research: Central nervous system tumors. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1022-1026.	1.5	74
81	Pediatric low-grade gliomas: implications of the biologic era. <i>Neuro-Oncology</i> , 2017, 19, now209.	1.2	73
82	Phase I Trial of Lapatinib in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4221-4227.	1.6	71
83	Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with medulloblastoma. <i>Neuro-Oncology</i> , 2010, 12, 1311-7.	1.2	71
84	Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. <i>Cancer</i> , 2010, 116, 4632-4637.	4.1	70
85	A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. <i>Neuro-Oncology</i> , 2009, 11, 33-40.	1.2	69
86	Posterior fossa syndrome and long-term neuropsychological outcomes among children treated for medulloblastoma on a multi-institutional, prospective study. <i>Neuro-Oncology</i> , 2017, 19, 1673-1682.	1.2	68
87	High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors. <i>Cancer</i> , 2008, 112, 1345-1353.	4.1	67
88	Critical Combinations of Radiation Dose and Volume Predict Intelligence Quotient and Academic Achievement Scores After Craniospinal Irradiation in Children With Medulloblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 554-561.	0.8	65
89	Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation. <i>Cancer Cell</i> , 2019, 35, 95-110.e8.	16.8	65
90	Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. <i>Acta Neuropathologica</i> , 2020, 139, 223-241.	7.7	65

#	ARTICLE	IF	CITATIONS
91	Current therapy for medulloblastoma. <i>Current Treatment Options in Neurology</i> , 2006, 8, 319-334.	1.8	64
92	Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children. <i>Neuro-Oncology</i> , 2015, 17, 882-888.	1.2	64
93	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. <i>Cancer Cell</i> , 2021, 39, 1519-1530.e4.	16.8	64
94	Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial. <i>Neuro-Oncology</i> , 2019, 21, 1319-1330.	1.2	63
95	Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. <i>Neuro-Oncology</i> , 2014, 16, 848-855.	1.2	62
96	MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas. <i>Acta Neuropathologica</i> , 2010, 120, 731-743.	7.7	61
97	Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma. <i>JAMA Oncology</i> , 2021, 7, 1313.	7.1	61
98	Necrosis After Craniospinal Irradiation: Results From a Prospective Series of Children With Central Nervous System Embryonal Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e655-e660.	0.8	59
99	Reirradiation of recurrent medulloblastoma: Does clinical benefit outweigh risk for toxicity?. <i>Cancer</i> , 2014, 120, 3731-3737.	4.1	58
100	Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3388-3395.	1.6	58
101	Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: A phase I/II study. , 1998, 30, 28-33.		56
102	Sequencing of Local Therapy Affects the Pattern of Treatment Failure and Survival in Children With Atypical Teratoid Rhabdoid Tumors of the Central Nervous System. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1756-1763.	0.8	56
103	Treatment-induced hearing loss and adult social outcomes in survivors of childhood CNS and non-CNS solid tumors: Results from the St. Jude Lifetime Cohort Study. <i>Cancer</i> , 2015, 121, 4053-4061.	4.1	56
104	Imaging Patterns and Outcome of Posterior Reversible Encephalopathy Syndrome During Childhood Cancer Treatment. <i>Pediatric Blood and Cancer</i> , 2016, 63, 523-526.	1.5	54
105	Hypothalamic-Pituitary Disorders in Childhood Cancer Survivors: Prevalence, Risk Factors and Long-Term Health Outcomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6101-6115.	3.6	54
106	Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021. <i>Cancer Medicine</i> , 2016, 5, 1416-1424.	2.8	53
107	Medulloblastoma with Brain Stem Involvement: The Impact of Gross Total Resection on Outcome. <i>Pediatric Neurosurgery</i> , 1996, 25, 182-187.	0.7	50
108	Role of high-dose chemotherapy for recurrent medulloblastoma and other CNS primitive neuroectodermal tumors. <i>Pediatric Blood and Cancer</i> , 2010, 54, 649-651.	1.5	50

#	ARTICLE	IF	CITATIONS
109	Attainment of Functional and Social Independence in Adult Survivors of Pediatric CNS Tumors: A Report From the St Jude Lifetime Cohort Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2762-2769.	1.6	50
110	Germline <i>GPR161</i> Mutations Predispose to Pediatric Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 43-50.	1.6	50
111	Association between hippocampal dose and memory in survivors of childhood or adolescent low-grade glioma: a 10-year neurocognitive longitudinal study. <i>Neuro-Oncology</i> , 2019, 21, 1175-1183.	1.2	46
112	Central precocious puberty following the diagnosis and treatment of paediatric cancer and central nervous system tumours: presentation and long-term outcomes. <i>Clinical Endocrinology</i> , 2016, 84, 361-371.	2.4	45
113	Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource. <i>Acta Neuropathologica</i> , 2020, 140, 209-225.	7.7	45
114	Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). <i>Oncotarget</i> , 2020, 11, 1942-1952.	1.8	45
115	Algorithm for nutritional support: Experience of the metabolic and infusion support service of St. Jude Children's Research Hospital. <i>International Journal of Cancer</i> , 1998, 78, 76-80.	5.1	44
116	Subsequent neoplasms in survivors of childhood central nervous system tumors: risk after modern multimodal therapy. <i>Neuro-Oncology</i> , 2015, 17, 448-456.	1.2	44
117	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. <i>Acta Neuropathologica</i> , 2021, 141, 771-785.	7.7	44
118	Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. <i>Clinical Cancer Research</i> , 2002, 8, 2202-9.	7.0	44
119	Topoisomerase I interactive drugs in children with cancer. <i>Investigational New Drugs</i> , 1996, 14, 37-47.	2.6	42
120	Phase I Clinical Trial of Mafosfamide in Infants and Children Aged 3 Years or Younger With Newly Diagnosed Embryonal Tumors: A Pediatric Brain Tumor Consortium Study (PBTC-001). <i>Journal of Clinical Oncology</i> , 2005, 23, 525-531.	1.6	42
121	Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: Report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2014, 61, 102-106.	1.5	42
122	Metastatic Low-Grade Gliomas in Children: 20 Years' Experience at St. Jude Children's Research Hospital. <i>Pediatric Blood and Cancer</i> , 2016, 63, 62-70.	1.5	42
123	Conformal Radiation Therapy for Pediatric Patients with Low-Grade Glioma: Results from the Children's Oncology Group Phase 2 Study ACNS0221. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 861-868.	0.8	42
124	Brain Tumors. <i>Pediatric Clinics of North America</i> , 2015, 62, 167-178.	1.8	40
125	Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221). <i>Journal of Clinical Oncology</i> , 2020, 38, 223-231.	1.6	40
126	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	1.6	40

#	ARTICLE	IF	CITATIONS
127	Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas. <i>Acta Neuropathologica</i> , 2016, 131, 299-307.	7.7	38
128	Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i> , <i>ROS1</i> , or <i>ALK</i> aberrations (STARTRK-NG). <i>Neuro-Oncology</i> , 2022, 24, 1776-1789.	1.2	37
129	Parent-Reported Social Outcomes After Treatment for Pediatric Embryonal Tumors: A Prospective Longitudinal Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 4134-4140.	1.6	36
130	Concordance between the change and the International Society of Pediatric Oncology (<sc>SIOP</sc>) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 601-605.	1.5	36
131	Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27035.	1.5	36
132	Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. <i>Acta Neuropathologica</i> , 2020, 139, 259-271.	7.7	36
133	Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. <i>Clinical Cancer Research</i> , 2021, 27, 2879-2889.	7.0	35
134	Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study. <i>Neuro-Oncology</i> , 2021, 23, 1586-1596.	1.2	35
135	Working Memory Abilities Among Children Treated for Medulloblastoma: Parent Report and Child Performance. <i>Journal of Pediatric Psychology</i> , 2014, 39, 501-511.	2.1	34
136	Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. <i>European Journal of Cancer</i> , 2021, 157, 198-213.	2.8	34
137	Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11). <i>Cancer</i> , 2013, 119, 4180-4187.	4.1	33
138	A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study. <i>Neuro-Oncology</i> , 2015, 17, 1132-1138.	1.2	33
139	Cognitive Implications of Ototoxicity in Pediatric Patients With Embryonal Brain Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 1566-1575.	1.6	33
140	Association of Hearing Impairment With Neurocognition in Survivors of Childhood Cancer. <i>JAMA Oncology</i> , 2020, 6, 1363.	7.1	32
141	Clinical, imaging, and molecular analysis of pediatric pontine tumors lacking characteristic imaging features of DIPG. <i>Acta Neuropathologica Communications</i> , 2020, 8, 57.	5.2	32
142	Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas. <i>Frontiers in Oncology</i> , 2014, 4, 67.	2.8	31
143	Hypothalamic-Pituitary Axis Dysfunction in Survivors of Childhood CNS Tumors: Importance of Systematic Follow-Up and Early Endocrine Consultation. <i>Journal of Clinical Oncology</i> , 2016, 34, 4315-4319.	1.6	31
144	Tectal glioma as a distinct diagnostic entity: a comprehensive clinical, imaging, histologic and molecular analysis. <i>Acta Neuropathologica Communications</i> , 2018, 6, 101.	5.2	30

#	ARTICLE	IF	CITATIONS
145	Hemodynamic responses to visual stimulation in children with sickle cell anemia. <i>Brain Imaging and Behavior</i> , 2011, 5, 295-306.	2.1	28
146	Molecular Biology of Medulloblastoma: Will It Ever Make a Difference to Clinical Management?. <i>Journal of Neuro-Oncology</i> , 2005, 75, 273-278.	2.9	27
147	M1 Medulloblastoma: high risk at any age. <i>Journal of Neuro-Oncology</i> , 2008, 90, 351-355.	2.9	27
148	Current Treatment Options for Pediatric and Adult Patients With Ependymoma. <i>Current Treatment Options in Oncology</i> , 2012, 13, 465-477.	3.0	27
149	Lorlatinib in a Child with <i>ALK</i> -Fusion-Positive High-Grade Glioma. <i>New England Journal of Medicine</i> , 2021, 385, 761-763.	27.0	27
150	Molecular characteristics of pediatric high-grade gliomas. <i>CNS Oncology</i> , 2014, 3, 433-443.	3.0	26
151	Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous. <i>Acta Neuropathologica</i> , 2018, 136, 315-326.	7.7	26
152	Bithalamic gliomas may be molecularly distinct from their unilateral high-grade counterparts. <i>Brain Pathology</i> , 2018, 28, 112-120.	4.1	26
153	Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	26
154	A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26373.	1.5	25
155	Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. <i>Neuro-Oncology</i> , 2015, 17, 1620-1627.	1.2	24
156	Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29031.	1.5	24
157	Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report. <i>Neuro-Oncology</i> , 2022, 24, 655-664.	1.2	24
158	Children with minimal chance for cure: parent proxy of the child's health-related quality of life and the effect on parental physical and mental health during treatment. <i>Journal of Neuro-Oncology</i> , 2016, 129, 373-381.	2.9	23
159	Determination of methotrexate, 7-hydroxymethotrexate, and 2,4-diamino-10-methylpterotic acid by LC-MS/MS in plasma and cerebrospinal fluid and application in a pharmacokinetic analysis of high-dose methotrexate. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2016, 39, 745-751.	1.0	21
160	Computerized assessment of cognitive impairment among children undergoing radiation therapy for medulloblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 141, 403-411.	2.9	21
161	Pulmonary cryptosporidiosis and <i>Cryptococcus albidos</i> fungemia in a child with acute lymphocytic leukemia. , 1998, 31, 544-546.		20
162	Pubertal development and primary ovarian insufficiency in female survivors of embryonal brain tumors following risk-adapted craniospinal irradiation and adjuvant chemotherapy. <i>Pediatric Blood and Cancer</i> , 2015, 62, 329-334.	1.5	20

#	ARTICLE	IF	CITATIONS
163	Anesthesia Exposure during Therapy Predicts Neurocognitive Outcomes in Survivors of Childhood Medulloblastoma. <i>Journal of Pediatrics</i> , 2020, 223, 141-147.e4.	1.8	20
164	The effects of propofol on cerebral perfusion MRI in children. <i>Neuroradiology</i> , 2013, 55, 1049-1056.	2.2	19
165	Neurologic impairments from pediatric low-grade glioma by tumor location and timing of diagnosis. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27063.	1.5	19
166	A pilot study of vincristine, ifosfamide, and doxorubicin in the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas. , 1998, 30, 210-216.		18
167	Molecular genetics of medulloblastoma in children: diagnostic, therapeutic and prognostic implications. <i>Future Neurology</i> , 2019, 14, FNL8.	0.5	18
168	Unusual Cutaneous Toxicity Following Treatment With Dactinomycin: A Report of Two Cases. <i>Medical and Pediatric Oncology</i> , 1995, 24, 329-333.	1.0	17
169	Functional MRI in medulloblastoma survivors supports prophylactic reading intervention during tumor treatment. <i>Brain Imaging and Behavior</i> , 2016, 10, 258-271.	2.1	17
170	Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 362-371.	2.4	17
171	Neuropsychological outcomes of patients with low-grade glioma diagnosed during the first year of life. <i>Journal of Neuro-Oncology</i> , 2019, 141, 413-420.	2.9	16
172	Treatment burden and long-term health deficits of patients with low-grade gliomas or glioneuronal tumors diagnosed during the first year of life. <i>Cancer</i> , 2019, 125, 1163-1175.	4.1	16
173	Safety and efficacy of brainstem biopsy in children and young adults. <i>Journal of Neurosurgery: Pediatrics</i> , 2020, 26, 552-562.	1.3	16
174	Association Between Brain Substructure Dose and Cognitive Outcomes in Children With Medulloblastoma Treated on SJMB03: A Step Toward Substructure-Informed Planning. <i>Journal of Clinical Oncology</i> , 2022, 40, 83-95.	1.6	15
175	Effect of inpatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy. <i>Cancer</i> , 2003, 97, 2374-2380.	4.1	14
176	Pulmonary Function After Treatment for Embryonal Brain Tumors on SJMB03 That Included Craniospinal Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 47-53.	0.8	14
177	Long-term visual acuity outcomes after radiation therapy for sporadic optic pathway glioma. <i>Journal of Neuro-Oncology</i> , 2019, 144, 603-610.	2.9	14
178	Exposure-Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing. <i>Clinical Cancer Research</i> , 2020, 26, 1563-1573.	7.0	14
179	Genomics Paves the Way for Better Infant Medulloblastoma Therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 2010-2013.	1.6	14
180	Mortality in children with low-grade glioma or glioneuronal tumors: A single-institution study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26717.	1.5	13

#	ARTICLE	IF	CITATIONS
181	How parents cope with their child's diagnosis and treatment of an embryonal tumor: results of a prospective and longitudinal study. <i>Journal of Neuro-Oncology</i> , 2011, 105, 253-259.	2.9	12
182	Children with dorsal midbrain syndrome as a result of pineal tumors. <i>Journal of AAPOS</i> , 2017, 21, 34-38.	0.3	12
183	Isolated Optic Nerve Glioma in Children With and Without Neurofibromatosis: Retrospective Characterization and Analysis of Outcomes. <i>Journal of Child Neurology</i> , 2018, 33, 375-382.	1.4	12
184	Establishing a Preclinical Multidisciplinary Board for Brain Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 1654-1666.	7.0	12
185	Risk stratification in pediatric low-grade glioma and glioneuronal tumor treated with radiation therapy: an integrated clinicopathologic and molecular analysis. <i>Neuro-Oncology</i> , 2020, 22, 1203-1213.	1.2	12
186	Clinical Pharmacokinetics of Amifostine and WR1065 in Pediatric Patients with Medulloblastoma. <i>Clinical Cancer Research</i> , 2010, 16, 1049-1057.	7.0	11
187	Preclinical studies of 5-fluoro-2-deoxycytidine and tetrahydrouridine in pediatric brain tumors. <i>Journal of Neuro-Oncology</i> , 2016, 126, 225-234.	2.9	11
188	Evaluating pediatric spinal low-grade gliomas: a 30-year retrospective analysis. <i>Journal of Neuro-Oncology</i> , 2019, 145, 519-529.	2.9	11
189	Incidence and Outcomes of CNS Tumors in Chinese Children: Comparative Analysis With the Surveillance, Epidemiology, and End Results Program. <i>JCO Global Oncology</i> , 2020, 6, 704-721.	1.8	11
190	MRI Patterns of Extrapontine Lesion Extension in Diffuse Intrinsic Pontine Gliomas. <i>American Journal of Neuroradiology</i> , 2020, 41, 323-330.	2.4	11
191	Primary hypothyroidism in childhood cancer survivors: Prevalence, risk factors, and long-term consequences. <i>Cancer</i> , 2022, 128, 606-614.	4.1	11
192	Circulating tumor DNA profiling for childhood brain tumors: Technical challenges and evidence for utility. <i>Laboratory Investigation</i> , 2022, 102, 134-142.	3.7	11
193	Bridging the Gap in Access to Care for Children With CNS Tumors Worldwide. <i>JCO Global Oncology</i> , 2020, 6, 583-584.	1.8	10
194	Diagnostic delay in children with central nervous system tumors and the need to improve education. <i>Journal of Neuro-Oncology</i> , 2019, 145, 591-592.	2.9	9
195	Predictors of Cognitive Performance Among Infants Treated for Brain Tumors: Findings From a Multisite, Prospective, Longitudinal Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2350-2358.	1.6	9
196	Incidence of Germline Mutations in Cancer-Predisposition Genes in Children with Hematologic Malignancies: a Report from the Pediatric Cancer Genome Project. <i>Blood</i> , 2014, 124, 127-127.	1.4	9
197	Anatomic Neuroimaging Characteristics of Posterior Fossa Type A Ependymoma Subgroups. <i>American Journal of Neuroradiology</i> , 2021, 42, 2245-2250.	2.4	9
198	High-dose chemotherapy for recurrent medulloblastoma. <i>Cancer</i> , 2008, 112, 1643-1645.	4.1	8

#	ARTICLE	IF	CITATIONS
199	Isochromosome 17q, <i>MYC</i> amplification and large cell/anaplastic phenotype in a case of medulloblastoma with extracranial metastases. <i>Pediatric Blood and Cancer</i> , 2012, 59, 561-564.	1.5	8
200	The management of children and adolescents with medulloblastoma in low and middle income countries. <i>Pediatric Blood and Cancer</i> , 2015, 62, 549-550.	1.5	8
201	Spinal changes after craniospinal irradiation in pediatric patients. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28728.	1.5	8
202	Ovulation induction and oocyte retrieval for fertility preservation in young adolescents newly diagnosed with medulloblastoma: a case series. <i>Journal of Obstetrics and Gynaecology</i> , 2018, 38, 878-879.	0.9	7
203	Reoperation for Medulloblastoma Prior to Adjuvant Therapy. <i>Neurosurgery</i> , 2019, 84, 1050-1058.	1.1	7
204	WNT-activated embryonal tumors of the pineal region: ectopic medulloblastomas or a novel pineoblastoma subgroup?. <i>Acta Neuropathologica</i> , 2020, 140, 595-597.	7.7	7
205	Height after photon craniospinal irradiation in pediatric patients treated for central nervous system embryonal tumors. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28617.	1.5	7
206	A Phase 2 Trial of Response-Based Radiation Therapy for Localized Central Nervous System Germ Cell Tumors: Patterns of Failure and Radiation Dosimetry for Nongerminomatous Germ Cell Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 143-151.	0.8	7
207	Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor. <i>Neuro-Oncology</i> , 0, , .	1.2	7
208	Aprepitant Reduces Chemotherapy-Induced Vomiting in Children and Young Adults With Brain Tumors. <i>Journal of Pediatric Oncology Nursing</i> , 2014, 31, 277-283.	1.5	6
209	Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 829-838.	2.3	6
210	Creation of a successful multidisciplinary course in pediatric neuro-oncology with a systematic approach to curriculum development. <i>Cancer</i> , 2021, 127, 1126-1133.	4.1	6
211	Outcome and molecular analysis of young children with choroid plexus carcinoma treated with non-myeloablative therapy: results from the SJYC07 trial. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa168.	0.7	6
212	Population pharmacokinetic analysis of crizotinib in children with progressive/recurrent high-grade and diffuse intrinsic pontine gliomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 1009-1020.	2.3	6
213	DNA index of glial tumors in children: Correlation with tumor grade and prognosis. <i>Cancer</i> , 1996, 78, 881-886.	4.1	5
214	Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG. <i>Neuro-Oncology Advances</i> , 2021, 3, vda179.	0.7	5
215	Clinical Characteristics and Long-Term Outcomes of Movement Disorders in Childhood Thalamic Tumors. <i>Pediatric Neurology</i> , 2016, 65, 71-77.	2.1	4
216	Determining success rates of the current pharmacokinetically guided dosing approach of topotecan in pediatric oncology patients. <i>Pediatric Blood and Cancer</i> , 2018, 66, e27578.	1.5	3

#	ARTICLE	IF	CITATIONS
217	Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinoma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29172.	1.5	3
218	Pulmonary cryptosporidiosis and <i>Cryptococcus albidus</i> fungemia in a child with acute lymphocytic leukemia. <i>Medical and Pediatric Oncology</i> , 1998, 31, 544-546.	1.0	3
219	Profound hearing loss following surgery in pediatric patients with posterior fossa low-grade glioma. <i>Neuro-Oncology Practice</i> , 2018, 5, 96-103.	1.6	2
220	Neuroimaging Findings in Children with Constitutional Mismatch Repair Deficiency Syndrome. <i>American Journal of Neuroradiology</i> , 2020, 41, 904-910.	2.4	2
221	Handedness switching as a presenting sign for pediatric low-grade gliomas: An insight into brain plasticity from a short case series. <i>Journal of Pediatric Rehabilitation Medicine</i> , 2021, 14, 31-36.	0.5	2
222	Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study. <i>Neuro-Oncology</i> , 2022, 24, 1166-1175.	1.2	2
223	Prognostic value and functional consequences of cell cycle inhibitor p27Kip1 loss in medulloblastoma. <i>Biomarker Research</i> , 2013, 1, 14.	6.8	1
224	C11ORF95-RELA FUSIONS DRIVE ONCOGENIC NF-KB SIGNALING IN EPENDYMOMA. <i>Neuro-Oncology</i> , 2014, 16, iii16-iii16.	1.2	1
225	Residual Strabismus in Children Following Improvement of Cranial Nerve Palsies Affecting Ocular Ductions. <i>American Orthoptic Journal</i> , 2015, 65, 87-93.	0.3	1
226	Precision medicine for pediatric central nervous system tumors. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 55-57.	0.7	1
227	Medulloblastoma: Improving cure rates in tandem with reduction in short-term toxicities and long-term treatment-related morbidities. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28645.	1.5	1
228	Abstract 1357: Population pharmacokinetic analysis of crizotinib in children with progressive/recurrent high-grade and diffuse intrinsic pontine gliomas. , 2021, , .		1
229	Pretreatment Normal WM Magnetization Transfer Ratio Predicts Risk of Radiation Necrosis in Patients with Medulloblastoma. <i>American Journal of Neuroradiology</i> , 2022, 43, 299-303.	2.4	1
230	Social Problem Solving in Survivors of Pediatric Brain Tumor. <i>Journal of Pediatric Psychology</i> , 2022, , .	2.1	1
231	HGG-06. Phase 2 Study of Veliparib and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma without H3 K27M or BRAF Mutations: A Report from the Children's Oncology Group ACNS1721 Study. <i>Neuro-Oncology</i> , 2022, 24, i60-i61.	1.2	1
232	MEDB-69. Clinical and molecular meta-analysis of three major medulloblastoma clinical trials (ACNS0331, SJMB03, ACNS0332) uncovers novel strategies to improve risk-stratified therapy. <i>Neuro-Oncology</i> , 2022, 24, i122-i122.	1.2	1
233	MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma. <i>Neuro-Oncology</i> , 2022, 24, i124-i125.	1.2	1
234	ATRT-22. Outcomes for children with recurrent atypical teratoid rhabdoid tumor: A single institution study with updated molecular and germline analysis. <i>Neuro-Oncology</i> , 2022, 24, i8-i8.	1.2	1

#	ARTICLE	IF	CITATIONS
235	ED-27 * CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME IN MOVEMENT DISORDER IN CHILDHOOD THALAMIC TUMORS. Neuro-Oncology, 2014, 16, v71-v72.	1.2	0
236	Reply to "Assembling the brain trust: the multidisciplinary imperative in neuro-oncology". Nature Reviews Clinical Oncology, 2019, 16, 522-523.	27.6	0
237	Targeted Therapies for Pediatric Central Nervous System Tumors. , 2019, , 375-382.		0
238	Abstract PO-077: Image clustering of brain tumor patients using a deep neural network. , 2021, , .		0
239	BIOM-36. SERIAL ASSESSMENT OF MEASURABLE RESIDUAL DISEASE IN MEDULLOBLASTOMA LIQUID BIOPSIES. Neuro-Oncology, 2021, 23, vi18-vi19.	1.2	0
240	Population pharmacokinetics of crenolanib in children and young adults with brain tumors. Cancer Chemotherapy and Pharmacology, 2022, 89, 459-468.	2.3	0
241	MRI sequences and interslice gap influence leptomeningeal metastasis detection in children with brain tumors. Neuroradiology, 2022, , 1.	2.2	0
242	The posterior fossa syndrome questionnaire: using science to inform practice. Journal of Neuro-Oncology, 2022, , 1.	2.9	0
243	QOL-17. Neurocognitive outcomes after treatment for medulloblastoma with reduced primary site target volume margins. Neuro-Oncology, 2022, 24, i137-i137.	1.2	0
244	MEDB-29. Application of Rotterdam Post-Operative Cerebellar Mutism Syndrome Prediction Model to Patients Operated for Medulloblastoma in a Single Institution. Neuro-Oncology, 2022, 24, i111-i111.	1.2	0
245	INSP-09. Using genetically engineered mouse models and patient-derived orthotopic xenografts to develop new therapies for pediatric brain tumors.. Neuro-Oncology, 2022, 24, i188-i188.	1.2	0